The story of Viagra, originally marketed by copyright, presents a intricate case study for backers considering the pharmaceutical sector. Despite its early success and impact of billions in sales, the intellectual property end has opened the floodgates for generic medications, greatly diminishing profit prospects . This shift raises doubts about th